✦ LIBER ✦

Documentation and analysis of adverse event data in clinical trials: The German chronic myeloid leukemia study experience

✍ Scribed by Joerg Hasford; Hassan Ansari; Dorothy Dickson; Rudiger Hehlmann

Book ID: 113297670
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 46 KB
Volume: 13
Category: Article
ISSN: 0197-2456
DOI: 10.1016/0197-2456(92)90199-a

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Presentation and analysis of data on rad

Presentation and analysis of data on radiographic outcome in clinical trials: Experience from the TEMPO study

✍ Désirée van der Heijde; Robert Landewé; Lars Klareskog; Vicente Rodríguez-Valver 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 531 KB

## Abstract ## Objective To evaluate different methods of presentation and analysis of radiographic data in a rheumatoid arthritis (RA) randomized controlled trial. ## Methods A double‐blind randomized controlled trial including 682 patients with active RA who were treated with methotrexate, eta

Imatinib as the first-line treatment of

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

✍ Daniela Zackova; Hana Klamova; Ladislav Dusek; Jan Muzik; Katerina Machova Polak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 3 views

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH

Allogeneic stem cell transplantation pro

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

✍ Dreger, P.; Dohner, H.; Ritgen, M.; Bottcher, S.; Busch, R.; Dietrich, S.; Bunje 📂 Article 📅 2010 🏛 American Society of Hematology 🌐 English ⚖ 326 KB

Consolidation with alemtuzumab in patien

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)

✍ Wendtner, C-M; Ritgen, M; Schweighofer, C D; Fingerle-Rowson, G; Campe, H; Jäger 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 134 KB

The incidence of arthropathy adverse eve

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab

✍ Carlo Pincelli; Eric Henninger; Florence Casset-Semanaz 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 475 KB